Furthermore, the survival probability of the high- and low-risk groups was significantly different in glioma subgroups stratified by WHO grade (grade III and grade IV), IDH1 status, 1p/19q codeletion status, and MGMT promoter methylation status (Figures 10(d)–10(k)). The gene discussed is MGMT; the disease is central nervous system cancer.